305 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings? http://www.zacks.com/stock/news/584443/will-nuplazid-aid-growth-for-acadia-acad-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-584443 Oct 25, 2019 - During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies.
Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings? http://www.zacks.com/stock/news/584435/can-cf-drugs-drive-growth-for-vertex-vrtx-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-584435 Oct 25, 2019 - During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.
BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3 http://www.zacks.com/stock/news/582538/biomarins-bmrn-earnings-revenues-beat-estimates-in-q3?cid=CS-ZC-FT-analyst_blog|earnings_article-582538 Oct 24, 2019 - BioMarin (BMRN) rides high on earnings and revenue beat in the third quarter of 2019.
Acorda (ACOR) to Post Q3 Earnings: What's in the Cards? http://www.zacks.com/stock/news/582508/acorda-acor-to-post-q3-earnings-whats-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-582508 Oct 24, 2019 - During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.
Factors Setting the Tone for Celgene (CELG) Q3 Earnings http://www.zacks.com/stock/news/581825/factors-setting-the-tone-for-celgene-celg-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-581825 Oct 24, 2019 - Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q3 results.
Is a Beat in Store for Glaxo (GSK) This Earnings Season? http://www.zacks.com/stock/news/579086/is-a-beat-in-store-for-glaxo-gsk-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-579086 Oct 23, 2019 - Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales growth in the third quarter.
T-Mobile (TMUS) to Report Q3 Earnings: Is a Beat in Store? http://www.zacks.com/stock/news/578832/t-mobile-tmus-to-report-q3-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-578832 Oct 23, 2019 - Investments in new geographies and customer experience are likely to have aided T-Mobile's (TMUS) third-quarter 2019 financial and operating results.
What's in the Cards for Sarepta (SRPT) This Earnings Season? http://www.zacks.com/stock/news/577120/whats-in-the-cards-for-sarepta-srpt-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-577120 Oct 22, 2019 - Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.
What's in the Cards for AstraZeneca (AZN) in Q3 Earnings? http://www.zacks.com/stock/news/575739/whats-in-the-cards-for-astrazeneca-azn-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-575739 Oct 21, 2019 - AstraZeneca's (AZN) third-quarter result is expected to reflect the impact of new drug sales.
Why the Earnings Surprise Streak Could Continue for Incyte (INCY) http://www.zacks.com/stock/news/571171/why-the-earnings-surprise-streak-could-continue-for-incyte-incy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-571171 Oct 18, 2019 - Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pages: 123456789...31

<<<Page 4>